CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Marinus investors who were adversely affected by alleged securities fraud between March 17, 2021 and May 7, 2024. Follow the link below to get more information and be contacted by a member of our team: MRNS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. WHAT'S NEXT? If you suffered a loss in Marinus during the relevant time frame, you have until August 5, 2024 to request that ...

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the "Class Period"), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of p ...

Group 1 - The Rosen Law Firm is reminding investors who purchased Marinus Pharmaceuticals, Inc. securities between March 17, 2021, and May 7, 2024, of the August 5, 2024, lead plaintiff deadline in the securities class action [4][8] - Investors may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [2] - The lawsuit alleges that defendants made materially false and misleading statements regarding the risks associated with the RAISE trial and its implications for the company's operations [8] Group 2 - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5] - The firm has been recognized for its success in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [5] - Investors have the option to select their counsel or remain absent as class members, as no class has been certified yet [6]

Core Viewpoint - Marinus Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding the risks associated with their clinical trials, specifically the RAISE trial and its implications for the RAISE II trial [2]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as March 17, 2021, to May 7, 2024 [2]. - Allegations include that the defendants understated the risk of failing to meet early-stopping criteria in the RAISE trial and did not disclose the potential consequences of such failure, which could lead to stopping the RAISE II trial [2]. Group 2: Shareholder Actions - Shareholders who purchased MRNS shares during the class period are encouraged to register for the class action, with a deadline set for August 5, 2024 [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - A class action securities lawsuit has been filed against Marinus Pharmaceuticals, Inc. for alleged securities fraud affecting investors between March 17, 2021, and May 7, 2024 [4]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for Marinus investors who were adversely affected by alleged securities fraud during the specified time frame [1]. - Investors have until August 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [2]. - The complaint alleges that defendants made false statements and concealed risks related to the Randomized Therapy in Status Epilepticus Trial (RAISE), including the potential failure to meet early-stopping criteria and the implications for the Phase 3 RAISE II trial [5]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [3]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [6].

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, o ...

NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE); (2) defendants did not disclose that a possible conse ...

LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming August 5, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period"). On April 15, 2024, Marinus disclosed that its Phase 3 RAISE trial for the treatment of refractory ...

The Allegations: Robbins LLP is Investigating Allegations Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding the Viability of its Drug Candidate Then, on May 8, 2024, Marinus announced cost cutting measures, including to stop "the Phase 3 Raise II trial in RSE; future development in RSE will be assessed following review of the RAISE topline data[.]" That same day, Fierce Biotech published an article sharing that "Marinus lays off 20% of staff to steady ship after IV seizure med's phase 3 strugg ...

SO WHAT: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serv ...